CEO Sana Alajmovic on Enzymatica’s Strategic Direction and Future

Watch Enzymatica’s new CEO, Sana Alajmovic, as she visits the studio of BioStock for a conversation about her new role, the company’s commercial strategy, and the road ahead..

In the interview, she shares what attracted her to Enzymatica, how the clinical evidence supporting ColdZyme will be leveraged to gain market share, and how the company plans to grow through clear focus, strong partnerships, and international expansion.

Watch the full interview here: